Drug intelligence / Profile preview

umbilical cord-derived mesenchymal stem cells (Trustem)

Development stage
Unknown
Lead developer
TruStem Cell Therapy
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) developed by Trustem are an allogeneic cell therapy being evaluated for the treatment of severe COVID-19. These cells possess potent immunomodulatory and anti-inflammatory properties, which are hypothesized to mitigate the systemic hyperinflammation, often referred to as a cytokine storm, and acute respiratory distress syndrome (ARDS) associated with severe SARS-CoV-2 infection. By secreting various paracrine factors and interacting directly with immune cells, UC-MSCs can modulate the activity of T-cells, B-cells, and macrophages, promoting a transition from a pro-inflammatory to an anti-inflammatory environment and supporting lung tissue repair. The therapy is administered via intravenous infusion to provide systemic immunomodulation.

Other names
UC-MSCsUmbilical cord mesenchymal stem cellsCELMA

Beyond the preview

Go deeper on umbilical cord-derived mesenchymal stem cells (Trustem).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Trustem).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call